Introduction {#S1}
============

Heavy alcohol drinking and tobacco smoking are highly associated. In the general population, it is estimated that 23% of people smoke cigarettes, up to 50% of individuals with alcohol abuse or dependence smoke([@R12]), and as many as 30% of smokers are also alcohol-dependent ([@R33]). Daily and occasional smokers are more likely than never smokers to be hazardous drinkers or to meet criteria for an alcohol use diagnosis ([@R31]). Smokers consume twice as much alcohol as nonsmokers ([@R6]) and alcohol drinkers who also smoke use more cigarettes/day than non-alcohol-dependent smokers ([@R8]). The high comorbidity of smoking and drinking ([@R11]; [@R32]) may be due to several factors. **First, social/peer pressures and availability of alcohol and cigarettes provide an environment that is conducive to drinking and smoking.** Second, the effects of the drugs when used together may be additive or synergistic with regard to the reinforcing properties. Third, pharmacological effects or interactions of the drugs, such as changes in metabolism or cross-tolerance, may facilitate co-abuse. Fourth, genetic factors may contribute to this comorbidity. We hypothesize that in addition to these factors, there is an interaction of alcohol and tobacco smoking at the level of the dopamine (DA) and serotonin (5-HT) transporters.

A wealth of preclinical and clinical literature demonstrates the effects of both acute and chronic alcohol administration on the monoaminergic system \[for reviews see ([@R7]; [@R53])\]. Specifically, the mesolimbic dopamine system is the primary basis for the rewarding properties of most drugs of abuse, including alcohol ([@R9]). While nicotine, the primary addictive chemical in tobacco smoke, exerts its initial effects at the nicotinic acetylcholine receptor, its effects on the mesolimbic dopamine system are also well-documented ([@R22]). The serotonergic system is also implicated in both alcohol dependence ([@R53]) and tobacco smoking ([@R39]). Dysfunctional 5-HT ([@R19]) and DA system activity ([@R51]) may represent a vulnerability to alcohol dependence.

DA and 5-HT transporter availability has been examined *in vivo* in alcohol drinkers. Chronic alcohol consumption has been found to result in lower ([@R25]; [@R30]; [@R36]; [@R50]), higher ([@R30]; [@R47]), or unchanged ([@R54]) availability of DA transporters compared to control subjects. Specifically, chronic alcohol consumption is associated with lower DA transporter availability in human alcohol drinkers who were imaged up to 4 weeks after their last drink compared to control subjects. Interestingly, this lower DA transporter availability increases during acute withdrawal, e.g., during the first 5 days of abstinence in humans ([@R25]) and at 24 hours of abstinence in nonhuman primates ([@R30]).

5-HT transporter availability has been reported to be lower ([@R20]; [@R46]) and similar ([@R4]) in recent and long term abstinent alcoholics compared to controls. In nonhuman primates, higher brainstem 5-HT transporters were associated with reduced sensitivity to alcohol intoxication, which is a marker of vulnerability to develop alcohol dependence ([@R15]), and brainstem 5-HT transporter availability was positively correlated with amount of alcohol consumption ([@R16]). Taken together, these associated lines of research suggest an initial reduction in DA and 5-HT transporter availability during acute withdrawal, which increases over time in alcohol-dependent subjects compared to healthy subjects. Importantly, despite the high comorbidity of tobacco smoking with alcoholism, the majority of these studies have not controlled for smoking status.

The development and validation of \[^123^\]β-CIT (2 β-carbomethoxy-3 β-(4-iodophenyl)tropane) for use with single photon emission computed tomography (SPECT) has allowed the simultaneous examination of DA and 5-HT transporter availability in a region dependent manner ([@R37]; [@R38]). Here, we used \[^123^\]β-CIT SPECT to delineate the interactions of alcohol and comorbid alcohol and tobacco smoking on DA and 5-HT transporter availability during acute alcohol withdrawal (\< 1 week) ([@R43]).

Materials and Methods {#S2}
=====================

Subjects {#S3}
--------

14 heavy alcohol drinkers (35.0 ± 12.0 y; age range 21--54; 5 women, 9 men; 1 Hispanic, 4 African American, 9 Caucasian) and 14 healthy controls (38.3 ± 10.0 y; age range 21--54; 7 women, 7 men; 2 African American, 12 Caucasian) participated in the study. In each group there were 8 nonsmokers and 6 smokers ([Table 1](#T1){ref-type="table"}). For simplicity we refer to the groups as alcohol smokers, alcohol nonsmokers, control smokers and control nonsmokers throughout the paper. A negative breathalyzer reading was required prior to initiating the intake appointment or brain imaging scans. Eligibility was determined as follows. Alcohol drinkers consumed at least 25 drinks per month based on self-report obtained using the Timeline FollowBack Interview ([@R41]). Control subjects, e.g., nondrinkers, were required to drink less than 10 drinks per year and could not have a history of alcohol abuse or dependence. Smoking status was verified by plasma cotinine levels \>150 ng/mL on the day of intake. Nonsmokers were required to have smoked less than 100 cigarettes in their lifetime and none in the previous 2 years, with plasma cotinine levels \<50 ng/mL on the day of intake. In addition, all subjects had a medical examination by a study physician to exclude any major medical issues or neurological disorders. This included a physical examination, electrocardiogram, serum chemistries, thyroid function studies, complete blood count, urinalysis, and urine toxicology screening. Subjects were given structured interviews using the SCID to rule out any Axis I Disorder except Alcohol Abuse or Dependence or Nicotine Dependence. All subjects had no history of significant medical illness or major head trauma. **All subjects had no use** of any psychotropic medications or herbal products during the 6 months prior to their participation. All women of childbearing age were required to have a negative pregnancy test during the screening process and prior to radiotracer injection on each study day. All healthy women were included; we did not exclude subjects for menstrual cycle irregularities or hormonal birth control. Menstrual cycle phase data was not collected. After complete description of the study to the subjects, written informed consent was obtained.

Alcohol drinkers were given a variety of assessments to determine demographic and other behavioral information. Assessments of alcohol drinking behavior included the Timeline Followback ([@R41]), Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) ([@R45]), Alcohol Dependence Scale (ADS) ([@R40]) and assessments of mood included the Beck Depression Inventory (BDI) ([@R3]) and the Center for Epidemiologic Studies Depression Scale (CES-D) ([@R35]).

\[^123^\]β-CIT SPECT and magnetic resonance imaging scans {#S4}
---------------------------------------------------------

The radiotracer \[^123^\]β-CIT was synthesized from the tributylstanyl precursor, with a radiochemical purity \> 97%, as previously described ([@R2]). On Day 1 of the study, subjects were pretreated with stable iodine approximately 30 min prior to radiotracer injection to limit thyroid uptake of ^123^I. \[^123^\]β-CIT was administered by bolus intravenous injection to alcohol drinkers 220.5 ± 23.3 MBq and control subjects 223.3 ± 8.7 MBq. Subjects returned the next day and were scanned 21--24 hours after radiotracer injection. Prior to imaging, 5 external fiducial markers of ^123^I were placed on the subjects head. One 24-minute emission scan and one 15-min simultaneous transmission and emission scan were obtained on a Picker Prism 3000 three-headed camera (Phillips, Cleveland, Ohio) equipped with a low-energy, ultra-high resolution fanbeam collimator (photopeak window 159 keV ± 10%, matrix 128 × 128) with a uniform sensitivity across the field of view. A ^57^Co-distributed source was measured with each experiment to control for daily variation in camera sensitivity. The axial resolution (full width at half maximum) of the camera was 12.2 mm, measured with a ^123^I line source in water in a cylindrical phantom. Blood was drawn on Day 1 prior to radiotracer injection and approximately 21 hours after injection to determine radiotracer metabolism and protein binding, or f~P~.

MRI was performed on a 1.5 Tesla GE Signa device (TR=25 milliseconds, TE=5 milliseconds, number of excitations=2, matrix=256×256 pixels, and field of view=24 cm).

Image analysis and outcome measure {#S5}
----------------------------------

\[^123^\]β-CIT labels DA and 5-HT transporters in a region specific manner. Specifically, \[^123^\]β-CIT labels DA transporters in the striatum and 5-HT transporters in the diencephalon and brainstem ([@R27]). SPECT images were analyzed with an MRI-based region-of-interest (ROI) approach as previously described ([@R42]; [@R44]). Briefly, emission data were reconstructed and a nonuniform attenuation correction was applied. Then, the MRI was coregistered to the emission scan to provide an anatomical guide for the placement of two-dimensional ROIs using MEDx software (Medical Numerics, Inc.). The chosen ROIs are those known to contain DA transporters, e.g., caudate and putamen that are averaged into one striatal region, 5-HT transporters, e.g., diencephalon and brainstem, and the cerebellum, which is used a background region. Two raters conducted the analysis. Variability between the raters was less than 12 % across regions of interest. The mean of the two raters is reported.

The primary outcome measure used was *BP*~P~, which is proportional to the binding potential (binding potential, in mL/g, equal to receptor number divided by receptor affinity) defined as follows: (specific -- nondisplaceable uptake) / total parent in plasma. It is computed as (region of interest activity -- cerebellum) / total parent in plasma. The cerebellum, which has no detectable levels of DA transporters and minimal levels of 5-HT transporters, is used as the background region. To control for differences in radiotracer metabolism and protein binding, the measures of total plasma parent concentration, f~P~ (protein binding), and free plasma parent concentration, defined as total parent concentration \* f~P~, were compared between groups.

Statistical Analysis {#S6}
--------------------

All outcomes were tested for normality using Kolmogorov-Smirnov test statistics and normal probability plots. DA and 5-HT transporter availability and V~2~ values (cerebellum uptake/total parent) were approximately normal. Radiotracer metabolism and protein binding values, e.g., f~P~, free parent, and total parent, were approximately normal after log transformation and thus, **the log transformed** values were used for analysis. Each outcome was evaluated using two-way ANOVA models where group (alcohol drinkers vs. controls) and smoking status (smokers vs. nonsmokers) were included as between-subject explanatory factors. Group comparisons within each level of smoking status were made to interpret significant interactions. These latter two comparisons were adjusted for Type I error using the Bonferroni correction. In the above models, age and gender were considered as potential covariates but were dropped for parsimony as neither of these variables was significant. Potential associations between brain and alcohol measures were assessed using correlation analysis. Analyses were performed using SAS, version 9.1 (Cary, NC) and all tests were considered statistically significant at P\<0.05.

Results {#S7}
=======

Group Characteristics {#S8}
---------------------

Twenty-eight subjects composed of 14 controls and 14 alcohol drinkers with 8 nonsmokers and 6 smokers per group participated in the study ([Table 1](#T1){ref-type="table"}). Alcohol drinkers were imaged between 1 and 5 days after their last drink. Alcohol smokers and nonsmokers did not differ significantly in average number of drinks per month, years drinking or the ADS. Alcohol smokers and control smokers did not differ significantly in numbers of cigarettes smoked per day, years smoked or FTND. Control subjects denied drinking alcohol within the month prior to the scan, no control subject reported drinking more than 8 drinks in a one-year period, and control subjects denied use of other illicit or psychotropic drugs.

DA transporter availability {#S9}
---------------------------

Overall striatal DA transporter levels were significantly higher in alcohol drinkers versus controls (F(1,24)=4.9, P=.04). Additionally, the group by smoking interaction was significant (F(1,24)=4.4, P=.05)) which was driven by greater DA transporter availability among alcohol nonsmokers versus control nonsmokers (F(1,24)=10.9, adjusted P=.006), with no difference between alcohol smokers and control smokers (F(1,24)=.01, adjusted P=1.0) (See [Figure 1](#F1){ref-type="fig"}).

5-HT transporter availability {#S10}
-----------------------------

A significant group by smoking status interaction was observed when assessing 5-HT transporter availability in both the diencephalon (F(1,24)=7.7, P=.01) and brainstem (F(1,24)=14.1, P=.001). Specifically, alcohol nonsmokers had significantly greater diencephalon (F(1,24)=6.2, adjusted P=.04) and brainstem (F(1,24)=23.5, adjusted P\<.0002) 5-HT transporter availability compared to control nonsmokers, whereas diencephalon (F(1,24)=2.3, adjusted P=.30) and brainstem (F(1,24)=0.58, adjusted P=.90) 5-HT transporter availability did not differ significantly between alcohol smokers and control smokers (See [Figure 2](#F2){ref-type="fig"}).

V~2~ values (cerebellum uptake/total parent) were compared between groups to ensure that group differences were not due to differences in nondisplaceable uptake. Again, a significant interaction was observed between group and smoking status (F(1,24)=11.3, P=.003), which was driven by significantly higher V~2~ levels among alcohol nonsmokers compared to control nonsmokers (F(1,24)=22.8, adjusted P\<.0002), with no group differences observed among smokers (F(1,24)=0.1, adjusted P=1.0). Higher V~2~ levels could be attributed to the small but detectable number of 5-HT transporters in the vermis of the cerebellum ([@R1]; [@R28]). Importantly, cerebellar V~2~ levels were not lower in the alcohol nonsmokers as would be expected if there was significant atrophy of the cerebellum, indicating that the higher numbers of DA and 5-HT transporters in other brain areas are not due to group differences in nondisplaceable uptake.

Radiotracer metabolism and protein binding {#S11}
------------------------------------------

Radiotracer metabolism and protein binding values were also examined between groups. Significantly lower levels of both total parent (F(1,24)=8.5, P=.008) and free parent, defined as f~P~ \* total parent (F(1,24)=6.3, P=.02), were observed in alcohol drinkers compared to controls. While there were no significant main or interactive effects of smoking on each of these variables (all P\>.28), the observed group differences were primarily driven by significantly lower total (F(1,24)=9.3, adjusted P=.012) and free (F(1,24)=7.4, adjusted P=.02) parent levels among alcohol nonsmokers versus control nonsmokers. This finding suggests that alcohol nonsmokers had faster metabolism of \[^123^I\]β-CIT. By using the outcome measure *BP*~P~ we correct for group differences in radiotracer metabolism.

Correlations between DA and 5-HT transporters and alcohol use history {#S12}
---------------------------------------------------------------------

Pearson correlations were performed between striatal DA and brainstem and diencephalon 5-HT transporter availability and alcohol measures including days since last drink, average drinks per month, years of drinking, and scores on the ADS, BDI and CES-D. There was a significant positive correlation between days since last drink and diencephalon (r=.60, P=.02) and brainstem (r=.54, P=.05) 5-HT availability (See [Figure 3](#F3){ref-type="fig"}). However, stratified analysis revealed these associations present in nonsmokers (r=.79, P=.02 and r=.79, P=.02 for diencephalon and brainstem, respectively) but not smokers (r=.07, P=.90 and r=.03, P=.95, respectively.) There were no significant correlations between striatal DA and brainstem and diencephalon 5-HT transporter availability and other alcohol or depression measures.

Discussion {#S13}
==========

In the present study, we report significantly higher striatal DA transporters in alcoholic nonsmokers but not alcoholic smokers during acute withdrawal. A similar pattern was noted also for 5-HT transporters with higher diencephalon and brainstem availability in the alcoholic nonsmokers but not alcoholic smokers. The significant positive correlation between diencephalon and brainstem 5-HT transporter availability and days since last drink in the alcoholic nonsmokers suggests that the higher availability was due to a compensatory increase in response to acute withdrawal from alcohol.

Given that V~2~ is an indirect measure of cerebellar atrophy and is significantly higher in alcohol nonsmokers compared to controls it is unlikely that the higher DA and 5-HT transporter availability is due to atrophy of the reference region, e.g., the cerebellum. While it is unexpected to have higher numbers of V~2~ in the reference region, this is not surprising given that low, but detectable levels of 5-HT transporters have been measured in the vermis of the cerebellum ([@R1]; [@R28]). While studies in control subjects demonstrate no significant measurable levels of 5-HT transporters in the cerebellum ([@R42]), after alcohol exposure and withdrawal the measurable numbers may become more significant. This theory needs to be validated in a future study **with a more selective paradigm.**

This study differs from studies showing a decrease in DA transporter availability in recently abstinent alcoholics *in vivo* up to 4 weeks of abstinence ([@R25]), postmortem, up to 10 hr after the last drink ([@R50]) and after chronic alcohol and 1 day of withdrawal in vervet monkeys ([@R30]), but is consistent with results indicating increased DA transporter availability in alcohol-preferring versus non-preferring monkeys ([@R30]). Notably, there was a decrease in DA transporter availability after chronic alcohol compared to controls, which then increased during acute withdrawal ([@R25]; [@R30]) and in some subjects approached or surpassed the level of DA transporter availability in control subjects ([@R25]).

The main differences between previous studies examining DA transporter availability in alcoholics and controls and the current study are 1) the systematic examination of tobacco smoking in the current study and 2) the severity of alcohol dependence. First, higher availability of DA transporters in alcohol nonsmokers but not smokers compared to controls suggests that smoking suppresses the alcohol-induced increase in DA transporter availability. The previous *in vivo* study ([@R25]) did not control for smoking, thus it is not clear whether there is a similar effect of comorbid tobacco smoking in chronic severe alcohol dependence. Second, subjects in the current study exhibit a range of alcohol consumption, from heavy drinkers to subjects that meet dependence (e.g., a range of 25--428 drinks/month), and did not require detoxification or inpatient hospitalization prior to withdrawal. Thus, this study may highlight a difference in DA transporter availability between alcoholics and heavy drinkers. It is possible that alcoholics have an altered "set point" in DA transporter availability compared to both healthy controls and to heavy alcohol drinkers ([@R23]). Lower DA transporters in alcohol drinkers have been hypothesized to be due to a downregulation of DA transporters in response to chronic alcohol consumption. In this study the subjects had been drinking for an average of 19 years (range 6--40 years) suggesting that the chronicity of drinking alone does not lead to lower DA transporters, but the amount of alcohol consumed is also a key part. It is possible that a subsyndromal level of alcohol drinking leads to a compensatory increase in DA transporter availability, measured during acute withdrawal. Indeed, it is interesting that [@R30] similarly found increased DA transporters in alcohol-preferring monkeys that had not chronically consumed large quantities of alcohol, and notably were nicotine-naive. Thus, a higher DA transporter availability is likely linked to lower DA tone, and may indicate a vulnerability to alcohol dependence. Taken together, these studies suggest that moderate to heavy drinking leads to higher DA transporter availability that is suppressed by tobacco smoking. More severe alcohol dependence may be associated with lower DA transporters and may also be modulated by tobacco smoking. Studies designed to address this question in more severe alcoholic populations need to be done within the first week of alcohol withdrawal.

These results extend the findings from previous studies that demonstrated lower 5-HT transporter availability in alcoholics abstinent for \> 3 weeks ([@R20]; [@R46]). Specifically, lower midbrain and brainstem 5-HT transporter availability was found in alcohol-dependent men after 3--5 weeks ([@R20]) and at least 2 years ([@R46]) of abstinence compared to healthy controls, which was correlated with depression and anxiety during withdrawal ([@R20]). A more recent study reported no difference in 5-HT transporter availability between alcoholics (smokers and nonsmokers), who were abstinent an average of 14 days, and control nonsmokers using \[^11^C\]DASB ([@R4]), which is a more selective ligand for 5-HT transporters than \[^123^I\]β-CIT. In the present study we observed higher 5-HT transporter availability in both the diencephalons and brainstem of alcoholic nonsmokers versus control nonsmokers that was not evident in alcoholic nonsmokers. The significant positive correlation between diencephalon and brainstem 5-HT transporter availability and days since last drink, suggests that during acute withdrawal, there is a compensatory increase in 5-HT transporters in nonsmokers but not smokers, suggesting that smoking suppresses the alcohol-induced increase in 5-HT transporter availability over the first week of abstinence. Of note, there are limitations to \[^123^\]β-CIT SPECT measurement of 5-HT transporter availability, e.g., the radiotracer may be influenced by endogenous 5-HT ([@R18]) and there are difficulties in quantification due to the low signal in the neocortex ([@R24]; [@R52]). However, the main finding of the current study lies in the modulation of 5-HT transporter availability by comorbid tobacco smoking and heavy drinking. Previous *in vivo* 5-HT transporter studies attempted to control for smoking in the alcoholic samples; however the studies did not include sufficient control smokers to systematically assess the effects of smoking between all groups. Specifically, the studies included either no control smokers ([@R4]) or two control smokers ([@R20]; [@R46]).

There are several reasons that DA and 5-HT transporter availability may differ between alcoholic smokers and nonsmokers. First, genetic differences may play a role such that alcoholics who smoke may be genetically distinct from alcoholics who do not smoke, and there is evidence to suggest that there is a common genetic component that contributes to alcohol and nicotine dependence ([@R48]). There may be a unique genetic contribution of the DA transporter gene to striatal DA transporter availability in alcoholics that is also correlated with alcohol withdrawal severity ([@R14]), and a possible link exists between reduced 5-HT transporter availability with the serotonin genotype in alcoholics ([@R17]). Second, there may be neurochemical differences between alcohol drinkers that smoke and do not smoke. Tobacco smoke contains up to 4000 chemicals including nicotine, and monoamine oxidase inhibitors (MAOIs) that alter the activity of DA and 5-HT. Specifically, chronic MAO inhibition increases extracellular ([@R26]) and tissue ([@R21]) DA levels. Consistently, low platelet MAO activity has been reported in both alcoholics ([@R13]; [@R55]; [@R57]) and tobacco smokers ([@R56]). We propose that chronic MAO inhibition from tobacco smoking increases DA release, and together with the increased DA release from heavy alcohol drinking, leads to a downregulation of the DA transporter in alcoholic smokers compared to the alcoholic nonsmokers. Notably, a previous study found no direct effect of tobacco smoking on the DA transporter ([@R42]), which implies there is an interaction of tobacco smoking and alcohol drinking at the DA transporter.

There are several limitations to the study. First, due to the small sample size, the results should be interpreted with caution and they require replication. Specifically, there is some between-subject variability in the tobacco-smoker groups, most notably in DA transporter availability. However, the data were analyzed in the presence and absence of the subjects with the lowest DA and 5-HT transporter availability and significance of the results was maintained. Second, while it is known that there are sex differences in the availability of both 5-HT ([@R42]) and DA ([@R29]; [@R34]; [@R42]) transporter availability, there was no effect of sex in the current study. These previous studies were conducted in healthy subjects. One issue with controlling for menstrual cycle phase or hormone fluctuations in studies with problem drinkers and smokers is that alcohol ([@R10]) and tobacco smoking ([@R5]; [@R58]) can disrupt the menstrual cycle making it difficult to control for the menstrual cycle in this population. We did not control for hormonal fluctuations or menstrual cycle phase in the current study and this will have to be evaluated in a future study. Third, there are limitations to \[^123^I\]beta-CIT SPECT. Specifically, the radiotracer is not selective, but measures both striatal DA and brainstem and diencephalon 5-HT transporters. Additionally, \[^123^I\]beta-CIT is not sensitive to the measurement of DA transporters in the cortex, which were recently found to be higher in postmortem brain of alcohol-dependent individuals vs. controls ([@R49]).

In summary, high striatal DA and diencephalon and brainstem 5-HT transporter availability in alcohol nonsmokers during acute abstinence may reflect a neuroadaptive response to acute alcohol withdrawal, and/or a vulnerability or transition to more severe alcohol dependence. This effect is suppressed by tobacco smoking and may have implications for the design of treatment plans for alcoholics who also smoke. While additional studies are needed, it may be speculated that by suppressing the neuroadaptive change in DA and 5-HT transporters during acute abstinence, tobacco smoking may alleviate some of the withdrawal symptoms from alcohol. This suggests that alcoholic smokers desiring to quit drinking and smoking simultaneously should be encouraged to use nicotine replacement strategies or nicotinic agonist medication to help manage alcohol withdrawal symptoms.
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![Striatal \[^123^I\]β-CIT binding in controls and alcohol drinkers in the total group and by smoking status. a. The bar represents the mean in each group. Percent difference was calculated as \[(alcohol drinker -- control)/alcohol drinker x 100\]. In the total group, there was a 16% difference (P=0.04), in the nonsmokers a 26% difference (P=0.006), and in the smokers a 1% difference (P=1.0).](nihms104818f1){#F1}

![Diencephalon and brainstem \[^123^I\]β-CIT binding in controls and alcohol drinkers in the total group and by smoking status. a. In the total group, there was an 8% difference (P=0.01), in the nonsmokers a 26% difference (P=0.04), and in the smokers a −28% difference (P=0.30). b. In the total group, there was a 25% difference (P=0.001), in the nonsmokers a 42% difference (P\<0.0002), and in the smokers a −13% difference (P=0.90).](nihms104818f2){#F2}

![Diencephalon and brainstem \[^123^I\]β-CIT binding in alcohol drinkers in the total group and by smoking status as a function of days since last drink. a. Significant linear regression coefficients were found in the total group and in the nonsmokers, but not the smokers for both brain regions.](nihms104818f3){#F3}

###### 

Demographics and clinical characteristics of control and alcohol drinker nonsmokers and smokers.

                                      Total      Nonsmokers   Smokers                              
  ----------------------------------- ---------- ------------ ---------- ------------- ----------- -----------------------------------------
  **Age**                             38.4±9.9   35.0±12.0    38.8±8.3   34.0±11.9     37.8±12.6   36.5±13.1
  **Sex**                             8M; 6F     9M; 5F       4M; 4F     3M; 5F        4M; 2F      6M; 0F
  **Average drinks/month**                                    \-         196.5±139.9   \-          134.3±100.3
  **Years Drinking**                                          \-         17.9±11.0     \-          20.0±12.8
  **Days since last drink (range)**                           \-         1--5          \-          1--2
  **ADS**                                                     \-         3.6±2.7       \-          [\*](#TFN2){ref-type="table-fn"}7.0±2.7
  **Cigarettes/day**                                          \-         \-            24.2±4.9    20.0±6.3
  **Years Smoking**                                           \-         \-            22.2±9.7    17.4±12.6
  **FTND**                                                    \-         \-            5.8±2.5     3.8±1.8

Data presented are means ± standard deviation unless otherwise noted. There are no significant differences in any of the variables between groups. The CIWAAr was also given to all heavy alcohol drinking subjects on scan days. The scores were not elevated, and ranged from 0--1, thus are not shown.

Information only obtained for 3 of the 6 subjects.

###### 

DA and 5-HT Transporter Availability by Alcohol Drinking and Smoking Status:*BP*~P~ Mean (SD)

                     Nonsmokers              Smokers                                          
  ------------------ ------------ ---------- --------- --------- ---------- ---------- ------ -----
  DA Transporter                                                                              
     Striatum        306 (47)     411 (43)   26%       .006      311 (87)   313 (80)   1%     1.0
  5-HT Transporter                                                                            
     Diencephalon    85 (13)      115 (18)   26%       .04       95 (32)    74 (33)    −28%   .30
     Brainstem       51 (11)      88 (9)     42%       \<.0002   59 (14)    52 (25)    −13%   .90
